Metacrine Reports Second-Quarter 2022 Results
09 août 2022 16h05 HE
|
Metacrine, Inc.
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal...
Digestive Health Products Market to reach USD 79.2 Billion by 2030 growing at a CAGR of 8%: Straits Research
30 mai 2022 14h15 HE
|
Straits Research
New York, United States, May 30, 2022 (GLOBE NEWSWIRE) -- Digestive system health products are supplements that help people's digestive health by improving gut function. Foods, functional foods, and...
Biomerica Reports 111% Increase in Q3 Fiscal 2022 Revenues to $7.6 million vs. Q3 Fiscal 2021
14 avr. 2022 08h37 HE
|
Biomerica, Inc.
Q3 Net loss per share of $0.01 vs. a net loss of $0.18 per share from same period last year InFoods® IBS diagnostic-guided therapy clinical trial results demonstrated statistically significant...
Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome
08 févr. 2022 06h39 HE
|
Biomerica, Inc.
InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind using science, diet and technology to identify patient specific foods, which when eliminated, help reduce the symptoms of IBS...
Biomerica Reports Record Financial Results for Fiscal Second Quarter ended November 30, 2021
13 janv. 2022 08h19 HE
|
Biomerica, Inc.
Revenues up 239% over prior year fiscal second quarter Customer orders backlog of over $4.0 million at November 30, 2021 Walmart began in-store and online sales of Biomerica’s EZ Detect™ Colon...
Biomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to Approximately $4.6 Million
16 déc. 2021 08h19 HE
|
Biomerica, Inc.
InFoods® IBS Clinical Trial on Track for Completion in December with Topline Results Expected to be Announced in January, 2022. IRVINE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc....
Biomerica Receives Notice of Allowance from Canadian Patent Office for Patent Covering Irritable Bowel Syndrome (IBS) Food Sensitivity Testing & Treatment
04 nov. 2021 06h39 HE
|
Biomerica, Inc.
Studies show that 13-20% of Canadians suffer from IBS at any given time1. The lifetime risk for a Canadian to develop IBS is 30%1. IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc....
Biomerica expects Completion of Patient Enrollment for its InFoods® Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial this week
30 août 2021 08h19 HE
|
Biomerica, Inc.
Final patients to compete this double blinded trial by end of October. Top-Line trial results expected by year end.The InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind for...
Biomerica Announces Notice of Allowance for Patent on Product used to Diagnose and Treat Depression
11 août 2021 08h19 HE
|
Biomerica, Inc.
Hundreds of millions of people worldwide suffer from depression IRVINE, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today that the Japanese Patent Office has...
InveniAI Announces Successful Completion of Milestone in its Collaboration with PRISM BioLab Focused on Designing Novel Inflammasome-Targeted Therapeutic Candidates
20 juil. 2021 08h10 HE
|
InveniAI LLC
- Successful generation of INVA8003, a peptidomimetic inhibitor of PYCARD (often referred to as ASC, apoptosis-associated speck-like protein containing CARD) triggers milestone payment to PRISM BioLab...